**6. Conclusions**

With recent device innovations, there are more options than ever before for pediatric congenital heart disease patients. However, special considerations still need to be given to specific congenital anomalies and patients with single ventricles. Risks of anticoagulation with bleeding and thrombosis are also careful considerations. There has been tremendous progress in the realm of MCS for pediatric patients in end-stage heart failure, but more research focusing on device and pharmacologic improvements needs to be done.
